330results about "Phosphorous compound active ingredients" patented technology

Methods for enhancing weight loss, or preventing or treating obesity or other conditions related thereto, such as diabetes, involve administering a GLP-1 agonist together with, or prior to, administering a mitochondrial uncoupler. Use of the uncoupler increases weight loss and enhances treatment of obesity and obesity-related medical conditions, such as by preventing weight regain after cessation of administration of the GLP-1 agonist.

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

Provided in the present invention are a phosphorus-containing compound, a pharmaceutical composition and the use thereof. Specifically, provided are a compound as represented by formula I, a pharmaceutically acceptable salt, an ester, a stereoisomer, a tautomer, a polymorph, a solvate, a metabolite, an isotopic derivative or a prodrug thereof. The phosphorus-containing compound of the present invention can effectively treat diseases and conditions mediated by TEAD, such as cancer.

This present disclosure provides reliable methods and apparatus for delivering microdroplets containing an active pharmaceutical ingredient (API) to underlying substrates. A control system is provided to ensure that the API dosage is both accurate and repeatable.

Disclosed are newly designed polymeric compounds (lipid-polymer conjugates) useful for forming lipid bilayers and liposomes comprising them, lipid bilayers and liposomes formed thereby, and uses thereof. Also disclosed is a method of preparing a new design of a polymeric compound (lipid-polymer conjugate).

Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.

Disclosed herein are compounds, pharmaceutical compositions, and methods for treating RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer, that inhibit RIPK1.

Cationic pillar[n]arenes, e.g., positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillar[5-6]arene derivatives are capable of inhibiting or preventing biofilm formation, and facilitating existing biofilm decomposition. A composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, can include a pharmaceutically acceptable carrier, and a cationic pillar[n]ene.

The present disclosure relates to compounds of formula (I), which are formylpeptide 2 (FPR2) receptor agonists and / or formylpeptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods using the compounds to treat, for example, atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. TIFF2023533037000263.tif35138

Triphenylphosphonium hydroxytyrosol TPP-HT, its synthesis method and application in the preparation of drugs for improving aortic endothelial cell function. TPP-HT can significantly increase the reduction of human aortic endothelial cell activity caused by saturated fatty acids, inhibit the inflammatory response and oxidative stress caused by saturated fatty acids, and at the same time increase the synthesis of ATP in vascular endothelial cells and the expression of mitochondrial complex II. By anti-inflammatory and protecting mitochondrial function, it can prevent the occurrence and development of atherosclerosis. Therefore, TPP-HT has good application prospects in preventing cardiovascular diseases such as atherosclerosis caused by high-fat-induced endothelial damage, opening up a new medical approach for preventing a series of problems of cardiovascular diseases such as atherosclerosis caused by endothelial damage due to unbalanced dietary structure, and providing a new basis for the development of new drugs.

The present disclosure relates to a technique for synthesizing with high yield a novel compound targeting mitochondria through a simple process, and the novel compound synthesized thereby. The novel compound targeting mitochondria of the present disclosure can be synthesized with high yield through a simple process and the compound thus prepared and nanoparticles containing same exhibit the therapeutic effects of targeting mitochondria, inhibiting gastric cancer, and treating inflammatory bowel disease, and systemic sclerosis and thus can be utilized for mitochondrial targeting applications, as anticancer compositions, or as therapeutic compositions for immune diseases.

The present invention relates to compounds containing a phosphonium salt group, as well as related salts, double salts, solvates, and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of medical disorders and diseases, particularly in the treatment and prevention of cancer.

The present invention relates to an anti-tumor use of a phosphorus compound. Specifically, the present invention provides a use of a compound of formula (I), an optical isomer thereof, a racemate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof in preparation of a composition or a preparation, wherein the composition or the preparation is used for preventing and / or treating tumors. The compound of the present invention exhibits excellent precise therapeutic efficacy against tumors characterized by high expression of kinase B.

The disclosure relates to certain compounds that can be consumed by a human subject to modulate the levels of plasmalogens in the subject to provide improved health outcomes. The disclosure further relates to the formulation of said compounds, compositions comprising at least one compound, and uses thereof.

The present invention relates to compounds containing a phosphonium salt group, as well as related salts, double salts, solvates, and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of medical disorders and diseases, particularly in the treatment and prevention of cancer.

The invention belongs to the technical field of agricultural biology, and particularly relates to application of an endoplasmic reticulum protein antioxidant (reducing agent) in prevention and treatment of bombyx mori nuclear polyhedrosis virus. A screening test finds that the related endoplasmic reticulum protein antioxidants beta-mercaptoethanol (BME), dithiothreitol (DTT) and / or tris (2-carboxyethyl) phosphine (TCEP) have the effect of inhibiting the bombyx mori nuclear polyhedrosis virus (BmNPV), and the antioxidants interfere the replication and proliferation of the virus by destroying disulfide bonds in key proteins of the BmNPV, so that the bombyx mori nuclear polyhedrosis virus can be inhibited. The stability and activity of virions are directly influenced, so that the infection of the viruses on the silkworms is inhibited, a brand new thought is provided for the development of antiviral drugs of the silkworms, and the application value is good.

Compounds, compositions, and methods for inhibiting ENPP1 are provided. Embodiments of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell-impermeable. The ENPP1 inhibitor compound can act extracellularly and block the degradation of cGAMP. Similarly, pharmaceutical compositions and methods for treating cancer are provided. Embodiments of the method include administering a therapeutically effective amount of an ENPP1 inhibitor to a subject to treat the cancer in the subject. In certain cases, the cancer is a solid tumor cancer. Similarly, methods are provided in which radiation therapy is administered to a subject in conjunction with administering an ENPP1 inhibitor to the subject. In the subject methods, radiation therapy can be administered at a dosage and / or frequency effective to reduce radiation damage to the subject while still eliciting an immune response.

The present application provides a VVN001-containing ophthalmic composition comprising an active material selected from a sodium salt represented by formula I and / or a free acid thereof, and ophthalmic excipients, to reduce the ocular inflammatory response by inhibiting a T cell-mediated inflammatory response through the active material. The concentration of the buffering agent in current invention is very low and the final buffer capacity of this ophthalmic composition is very close to the buffering capacity of the tear, which is tear-friendly and comfortable, and to increase the average residence time of the active material of the present application, as well as to increase the bioavailability of the active material represented by formula I according to the present application.

The present application discloses a small molecule compound having a phosphorylated aromatic structure and application thereof. The compound and pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof provided in the present application or the pharmaceutical composition provided in the second aspect of the present invention, by targeting the TEAD palmitoyl pocket, effectively inhibits / blocks YAP-TEAD binding, inhibits / blocks the transcription function of YAP-TEAD, thereby preventing and / or treating diseases related to increased TEAD transcription levels and / or YAP phosphorylation disorders and / or Hippo signaling pathway disorders.

The present invention provides a method of treating ALK-negative / LTK-positive cancer in a subject, comprising administering to the subject a pharmaceutically-effective dose of a linear inhibitor of ALK. The invention is of particular utility in treating multiple myeloma, including proteasome inhibitor-resistant multiple myeloma.

Disclosed is a method for the prevention and / or treatment of a disease or disorder associated with a defect in hemoglobin protein activity or expression, or an innate immune response that is a type 1 or type 3 immune related immunodeficiency, comprising administering to a subject in need thereof a therapeutically effective amount of a substance X, or a pharmaceutical composition comprising said substance X, wherein said substance X is a compound of formula I, a pharma- ceutically acceptable salt or solvate thereof. JPEG2024529118000179.jpg2921

The present invention provides an ophthalmic composition containing VVN001. The ophthalmic composition containing VVN001 contains an active substance and an ophthalmic excipient, and the active substance is selected from the sodium salt represented by Formula I and / or the free acid of Formula I. The present invention reduces the inflammatory reaction in the eye by inhibiting the inflammatory reaction mediated by T cells by the active substance. The present invention further selects a low concentration of pH buffer concentration to match the buffer capacity of the pH buffer concentration in tears, is gentle to tears, has a strong sense of comfort, increases the mean residence time of the active substance of the present invention, and improves the bioavailability of the active substance represented by Formula I of the present invention. 【Chemical 1】 JPEG2025516407000025.jpg70136

The present disclosure provides herein, inter alia, methods of treating patients diagnosed with amyotrophic lateral sclerosis (ALS).

The present invention features methods of treating pain, e.g., pain associated with central sensitization, using modified NSAIDs, e.g., using sulindac phosphate.

This invention provides an antigen-binding protein that binds to proprotein converterase subtilisin kexin type 9 (PCSK9), as well as a method for using and producing the antigen-binding protein. [Solution] The present invention provides an isolated neutralizing antigen-binding protein that interacts with proprotein converterase subtilisin kexin type 9 (PCSK9), and which contains a specific amino acid sequence that binds to the PCSK9 protein and reduces the LDLR-reducing effect of PCSK9 on LDLR.

To provide a pharmaceutical composition useful for treating, alleviating, or inhibiting the progression of neurodegenerative diseases or conditions associated with tauopathy.SOLUTION: A pharmaceutical composition for reducing lipid peroxidation in a patient, comprising a compound of formula (I), or a salt thereof, wherein the concentration of the composition when administered to a patient is at least 20% of the liposomal lipid bilayer of the patient.SELECTED DRAWING: None